Skip to main content

CSF Aβ1–42, but not p-Tau181, Predicted Progression from Amnestic MCI to Alzheimer’s Disease Dementia

NeuroMolecular Medicine volume 20, pages 491–497 (2018)Cite this article

Abstract

The purpose of the study was to determine whether Aβ1–42 and p-Tau181 cerebral spinal fluid (CSF) levels can predict progression from amnestic mild cognitive impairment (aMCI) to Alzheimer’s disease dementia (ADD) in a 3-year follow-up study. All participants were evaluated blindly by a behavioral neurologist and a neuropsychologist, and classified according to the Petersen criteria for aMCI and according to the Clinical Dementia Rating (CDR) scale. Individuals were also submitted to lumbar puncture at baseline. Levels of Aβ1–42 and p-Tau181 were measured by immunoenzymatic assay. Values were adjusted for age and sex. Thirty-one of 33 (93.9%) participants completed follow-up. Approximately 39% of aMCI individuals progressed to ADD. The relative risk of developing ADD in those with Aβ1–42 CSF levels lower than 618.5 pg/mL was 17.4 times higher than in those whose levels were higher than 618.5 pg/mL (P = 0.003). p-Tau181 alone did not predict progression to ADD (P = 0.101). The relative risk in those with a p-Tau181/Aβ1–42 ratio higher than 0.135 was 5.7 times greater (P < 0.001). Aβ1–42 and p-Tau181 explained 40.1% of the verbal memory test subscore of the Consortium to Establish a Registry for Alzheimer’s Disease (ΔCERADs) variance (P = 0.008). Aβ1–42 strongly predicted progression from aMCI to ADD. p-Tau181 alone, or its relation to Aβ1–42, was inferior than Aβ1–42 alone as a predictor of progression to ADD.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  • Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., Snyder, P. J., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7(3), 270–279.

    Article  Google Scholar 

  • Almeida, O., & Almeida, S. (1999). Confiabilidade da versão brasileira da Escala de Depressão em Geriatria (GDS) versão reduzida. Arq Neuro-Psiquiatr, 57, 421–426.

    CAS  Article  Google Scholar 

  • Bertolucci, P. H., Okamoto, I. H., Brucki, S. M., Siviero, M. O., Toniolo Neto, J., & Ramos, L. R. (2001). Applicability of the CERAD neuropsychological battery to Brazilian elderly. Arq Neuropsiquiatr, 59(3-A), 532–536.

    CAS  Article  Google Scholar 

  • Bertolucci, P. H. F., Okamoto, I. H., Toniolo Neto, J., Ramos, L. R., & Brucki, S. M. D. 1998. Desempenho da populacao Brasileira na bateria neuropsicologica do Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) Revista de Psiquiatria Clínica, 25, 80–83.

    Google Scholar 

  • Brucki, S. M., Malheiros, S. M., Okamoto, I. H., & Bertolucci, P. H. (1997). Normative data on the verbal fluency test in the animal category in our milieu. Arquivos de Neuro-psiquiatria, 55(1), 56–61.

    CAS  Article  Google Scholar 

  • Buchhave, P., Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., & Hansson, O. (2012). Cerebrospinal fluid levels of β-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Archives of General Psychiatry, 69(1), 98–106.

    CAS  Article  Google Scholar 

  • Chandler, M. J., Lacritz, L. H., Hynan, L. S., Barnard, H. D., Allen, G., Deschner, M., Weiner, M. F., & Cullum, C. M. (2005). A total score for the CERAD neuropsychological battery. Neurology, 65(1), 102–106.

    CAS  Article  Google Scholar 

  • Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., & Cummings, J. L. (2014). Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. The Lancet Neurology, 13(6), 614–629.

    Article  Google Scholar 

  • Ferreira, D., Perestelo-Pérez, L., Westman, E., Wahlund, L. O., Sarría, A., & Serrano-Aguilar, P. (2014a). Meta-review of CSF core biomarkers in Alzheimer’s disease: The state-of-the-art after the new revised diagnostic criteria. Frontiers in Aging Neuroscience, 6, 47.

    PubMed  PubMed Central  Google Scholar 

  • Ferreira, D., Rivero-Santana, A., Perestelo-Pérez, L., Westman, E., Wahlund, L. O., Sarría, A., & Serrano-Aguilar, P. (2014b). Improving CSF biomarkers’ performance for predicting progression from mild cognitive impairment to Alzheimer’s disease by considering different confounding factors: A meta-analysis. Frontiers in Aging Neuroscience, 6, 287.

    PubMed  PubMed Central  Google Scholar 

  • Gifford, K. A., Liu, D., Damon, S. M., Chapman, W. G., Iii, R., Samuels, R. R., Lu, L. R., Jefferson, Z., Initiative, A. L., A.s.D.N (2015). Subjective memory complaint only relates to verbal episodic memory performance in mild cognitive impairment. Journal of Alzheimer’s Disease, 44(1), 309–318.

    CAS  Article  Google Scholar 

  • Haapalinna, F., Paajanen, T., Penttinen, J., Kokki, H., Kokki, M., Koivisto, A. M., Hartikainen, P., Solje, E., Hänninen, T., Remes, A. M., & Herukka, S. K. (2016). Low cerebrospinal fluid amyloid-beta concentration is associated with poorer delayed memory recall in women. Dementia and Geriatric Cognitive Disorders Extra, 6(2), 303–312.

    Article  Google Scholar 

  • Haldenwanger, A., Eling, P., Kastrup, A., & Hildebrandt, H. (2010). Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer’s disease. Journal of Alzheimer’s Disease, 22(3), 971–980.

    Article  Google Scholar 

  • Isaacs, B., & Kennie, A. T. (1973). The Set test as an aid to the detection of dementia in old people. The British Journal of Psychiatry, 123(575), 467–470.

    CAS  Article  Google Scholar 

  • Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Pankratz, V. S., Donohue, M. C., & Trojanowski, J. Q. (2013). Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. The Lancet Neurology, 12(2), 207–216.

    CAS  Article  Google Scholar 

  • Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. The Lancet Neurology, 9(1), 119–128.

    CAS  Article  Google Scholar 

  • Kaplan, E., Goodglass, H., & Weintraub, S. (1983). Boston naming test. Philadelphia: Lea & Febiger.

    Google Scholar 

  • McGeer, P. L., & McGeer, E. G. (2013). The amyloid cascade-inflammatory hypothesis of Alzheimer disease: Implications for therapy. Acta Neuropathology, 126(4), 479–497.

    CAS  Article  Google Scholar 

  • McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s and Dementia, 7(3), 263–269.

    Article  Google Scholar 

  • Memória, C. M., Yassuda, M. S., Nakano, E. Y., & Forlenza, O. V. (2013). Brief screening for mild cognitive impairment: Validation of the Brazilian version of the Montreal cognitive assessment. International Journal of Geriatric Psychiatry, 28(1), 34–40.

    Article  Google Scholar 

  • Michaud, T. L., Kane, R. L., McCarten, J. R., Gaugler, J. E., Nyman, J. A., Kuntz, K. M., & Initiative, A. S. D. N. (2015). Risk stratification using cerebrospinal fluid biomarkers in patients with mild cognitive impairment: An exploratory analysis. Journal of Alzheimer’s Disease, 47(3), 729–740.

    CAS  Article  Google Scholar 

  • Miotto, E. C., Sato, J., Lucia, M. C., Camargo, C. H., & Scaff, M. (2010). Development of an adapted version of the Boston Naming Test for Portuguese speakers. Revista Brasileira de Psiquiatria, 32(3), 279–282.

    Article  Google Scholar 

  • Molinuevo, J. L., Blennow, K., Dubois, B., Engelborghs, S., Lewczuk, P., Perret-Liaudet, A., Teunissen, C. E., & Parnetti, L. (2014). The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimer’s & Dementia, 10, 808–817

    Article  Google Scholar 

  • Morris, J. C. (1993). The clinical dementia rating (CDR): Current version and scoring rules. Neurology, 43(11), 2412–2414.

    CAS  Article  Google Scholar 

  • Morris, J. C., Blennow, K., Froelich, L., Nordberg, A., Soininen, H., Waldemar, G., Wahlund, L. O., & Dubois, B. (2014). Harmonized diagnostic criteria for Alzheimer’s disease: Recommendations. Journal of Internal Medicine, 275(3), 204–213.

    CAS  Article  Google Scholar 

  • Morris, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989). The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology, 39(9), 1159–1165.

    CAS  Article  Google Scholar 

  • Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatric Society, 53(4), 695–699.

    Article  Google Scholar 

  • Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine, 256(3), 183–194.

    CAS  Article  Google Scholar 

  • Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014). Mild cognitive impairment: A concept in evolution. Journal of Internal Medicine, 275(3), 214–228.

    CAS  Article  Google Scholar 

  • Prestia, A., Caroli, A., Wade, S. K., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A., Carter, S. F., Schöll, M., Choo, I. H., Nordberg, A., Scheltens, P., & Frisoni, G. B. (2015). Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer’s & Dementia, 11(10), 1191–1201.

    Article  Google Scholar 

  • Rami, L., Fortea, J., Bosch, B., Solé-Padullés, C., Lladó, A., Iranzo, A., Sánchez-Valle, R., & Molinuevo, J. L. (2011). Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. Journal of Alzheimer’s Disease, 23(2), 319–326.

    CAS  Article  Google Scholar 

  • Ritchie, C., Smailagic, N., Noel-Storr, A. H., Takwoingi, Y., Flicker, L., Mason, S. E., & McShane, R. 2014. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database System Review, 6, CD008782.

    Google Scholar 

  • Rizzi, L., Maria Portal, M., Batista, C. E. A., Missiaggia, L., & Roriz-Cruz, M. (2018). CSF Aβ1–42, but not p-Tau181, differentiates aMCI from SCI. Brain Research, 1678, 27–31.

    CAS  Article  Google Scholar 

  • Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer’s disease. American Journal of Psychiatry, 141(11), 1356–1364.

    CAS  Article  Google Scholar 

  • Samtani, M. N., Raghavan, N., Shi, Y., Novak, G., Farnum, M., Lobanov, V., Schultz, T., Yang, E., DiBernardo, A., Narayan, V. A., & Initiative, A. s. D. N. (2013). Disease progression model in subjects with mild cognitive impairment from the Alzheimer’s disease neuroimaging initiative: CSF biomarkers predict population subtypes. The British Journal of Clinical Pharmacology, 75(1), 146–161.

    Article  Google Scholar 

  • Schjønning Nielsen, M., Simonsen, A. H., Siersma, V., Hasselbalch, S. G., & Høgh, P. (2016). Are CSF biomarkers useful as prognostic indicators in diagnostically unresolved cognitively impaired patients in a normal clinical setting. Dementia and Geriatric Cognitive Disorders Extra, 6(3), 465–476.

    Article  Google Scholar 

  • Tang, W., Huang, Q., Wang, Y., Wang, Z. Y., & Yao, Y. Y. (2014). Assessment of CSF Aβ42 as an aid to discriminating Alzheimer’s disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies. Journal of Neurology Science, 345(1–2), 26–36.

    CAS  Article  Google Scholar 

  • Tondelli, M., Bedin, R., Chiari, A., Molinari, M. A., Bonifacio, G., Lelli, N., Trenti, T., & Nichelli, P. (2015). Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: A clinical cohort study. Clinical Chemistry Laboratory Medicine, 53(3), 453–460.

    CAS  Article  Google Scholar 

  • Trzepacz, P. T., Hochstetler, H., Wang, S., Walker, B., Saykin, A. J., & Initiative, A. S. D. N. (2015). Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatric, 15, 107.

    Article  Google Scholar 

  • Vos, S. J., van Rossum, I. A., Verhey, F., Knol, D. L., Soininen, H., Wahlund, L. O., Hampel, H., Tsolaki, M., Minthon, L., Frisoni, G. B., Froelich, L., Nobili, F., van der Flier, W., Blennow, K., Wolz, R., Scheltens, P., & Visser, P. J. (2013). Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 80(12), 1124–1132.

    Article  Google Scholar 

  • Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982). Development and validation of a geriatric depression screening scale: A preliminary report. Journal of Psychiatric Research, 17(1), 37–49.

    Article  Google Scholar 

  • Youden, W. J. (1950). Index for rating diagnostic tests. Cancer, 3(1), 32–35.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This study was supported by CAPES-CNPQ (Grant Number: 476387/2013-2) and FIPE (Process: 13-0009). All authors declare that their funding source had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.

Author information

Affiliations

  1. Division of Geriatric Neurology, Neurology Service, Hospital de Clínicas de Porto Alegre (HCPA), Ramiro Barcelos Street, 2350, Porto Alegre, 90035-903, RS, Brazil

    Liara Rizzi, Luciane Missiaggia & Matheus Roriz-Cruz

  2. School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, 90035-903, RS, Brazil

    Liara Rizzi, Luciane Missiaggia & Matheus Roriz-Cruz

Authors
  1. Liara Rizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luciane Missiaggia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matheus Roriz-Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Liara Rizzi.

Ethics declarations

Conflict of interest

The authors hereby declare that there are no actual or potential conflicts of interest that may have affected the discussion presented.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rizzi, L., Missiaggia, L. & Roriz-Cruz, M. CSF Aβ1–42, but not p-Tau181, Predicted Progression from Amnestic MCI to Alzheimer’s Disease Dementia. Neuromol Med 20, 491–497 (2018). https://doi.org/10.1007/s12017-018-8516-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12017-018-8516-8

Keywords

  • Alzheimer’s disease
  • Amyloid protein
  • CSF biomarkers
  • MCI
  • Tau